Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

HIV programmes world-wide currently make decisions regarding new antiretroviral therapy (ART) regimens with less side-effects and higher resistance barriers, which may improve adherence and viral suppression. Economic evaluation helps inform these decisions.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): AIDS

Title: AIDS (London, England)

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1473-5571

ISSN (Print): 0269-9370

Publication date (Electronic): Dec 15 2021

Volume: 35

Issue: Suppl 2

Affiliations

[1 ] Health Economics and Epidemiology Research Office (HERO), Department of Internal Medicine, School of Clinical Medicine.

[2 ] Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

[3 ] Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

[4 ] School of Public Health, Boston University, Boston, MA, USA.

Article

Publisher Item ID: 00002030-202112152-00009

DOI: 10.1097/QAD.0000000000003068

PubMed ID: 34848584

SO-VID: ff9f88f6-6ac4-4ff8-83a6-921a86317bb8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by